科兴制药：GB19注射液获临床试验批准

Group 1 - The core point of the article is that Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Pharmaceutical, has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for its innovative drug "GB19 injection," which targets BDCA2 (blood dendritic cell antigen 2) [1] Group 2 - The approval signifies a significant step in the development of Kexing's self-developed drug, indicating progress in the company's research and development efforts [1] - The drug "GB19 injection" is positioned as a targeted therapy, which may enhance treatment options in its therapeutic area [1] - This development reflects the growing focus on innovative drug research within the pharmaceutical industry in China [1]